30.07.2020
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
Cell Reports, 2020
A team of scientists, including researchers from Active Motif China, developed recombinant antibodies targeting SARS-CoV-2 and their work was recently published in the journal Cell Reports.
Several of these antibodies were strong binders to the SARS-CoV-2 Spike S1 protein and were able to effectively neutralize infectivity of the virus, suggesting that they could be further developed and used as therapeutics against COVID-19. Learn in the following article how Wan et al. identified 11 potent neutralizingantibodies against COVID-19 from 11convalescent patients targeting threemain epitopes on RBD.
Summary
Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC50 below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC50 within 10 nM, and the best one, 414-1, with IC50 of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.
SARS-CoV-2 Spike Antibodies used in this study are available through Biozol:
| Product name | Clone | Product code |
| SARS-CoV-2 Spike Antibody (AM009105) | 105-9 | ACM-91337 |
| SARS-CoV-2 Spike Antibody (AM038105) | 105-38 | ACM-91339 |
| SARS-CoV-2 Spike Antibody (AM043105) | 105-43 | ACM-91341 |
| SARS-CoV-2 Spike Antibody (AM004414) | 414-4 | ACM-91345 |
| SARS-CoV-2 Spike Antibody (AM005415) | 415-5 | ACM-91347 |
| SARS-CoV-2 Spike Antibody (AM002414) | 414-2 | ACM-91349 |
| SARS-CoV-2 Spike Antibody (AM006415) | 415-6 | ACM-91351 |
| SARS-CoV-2 Spike Antibody (AM032414) | 414-3-2 | ACM-91359 |
| SARS-CoV-2 Spike Antibody (AM001414) | 414-1 | ACM-91361 |
| SARS-CoV-2 Spike Antibody (AM015553) | 553-15 | ACM-91377 |
| SARS-CoV-2 Spike Antibody (AM002413) | 413-2 | ACM-91379 |
| SARS-CoV-2 Spike Antibody (AM020553) | 553-20 | ACM-91381 |
| SARS-CoV-2 Spike Antibody (AM005505) | 505-5 | ACM-91383 |
| SARS-CoV-2 Spike IgG/IgM Antibody (AM043105) | 105-43 | ACM-91385 |
| SARS-CoV-2 Spike Antibody (AM017553) | 553-17 | ACM-91387 |
